Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemtuzumab ozogamicin + all-trans retinoic acid
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Gemtuzumab ozogamicin + all-trans retinoic acid is a combination of an antibody-drug conjugate and a differentiation-inducing agent, investigated for treatment of acute myeloid leukemia (AML), primarily acute promyelocytic leukemia (APL) and other subtypes. Gemtuzumab ozogamicin is a humanized anti-CD33 monoclonal antibody conjugated to calicheamicin, a cytotoxic agent, which binds CD33 on leukemia cells, is internalized, and releases calicheamicin to cause DNA double-strand breaks and cell death[5][2]. All-trans retinoic acid (ATRA) acts by binding retinoic acid receptors (RARs) and induces differentiation and apoptosis of leukemic cells[4][6]. This combination aims to harness the cytotoxicity of gemtuzumab ozogamicin and the differentiation/apoptosis-inducing activity of ATRA to improve outcomes in patients, especially those unable to tolerate conventional chemotherapy[1][3].
02
Targets
CD33 (Myeloid cell surface antigen CD33)RARA (Retinoic acid receptor alpha)RAR (Retinoic acid receptor)
Beyond the preview
Go deeper on gemtuzumab ozogamicin + all-trans retinoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemtuzumab ozogamicin + all-trans retinoic acid.